Fate Therapeutics, Inc. - FATE STOCK NEWS

Fate Therapeutics will host a conference call on February 24, 2021, at 5:00 p.m. ET to discuss its Q4 and full year 2020 financial results and provide a corporate update. The call can be accessed by dialing 877-303-6235 (domestic) or 631-291-4837 (international) with conference ID 6368962. Additionally, a live audio webcast will be available on the company's website, with an archived version accessible two hours post-event. Fate Therapeutics focuses on programmed cellular immunotherapies for cancer and holds a leadership position in the development of universal iPSC cell products.

Fate Therapeutics (NASDAQ: FATE) has completed an underwritten public offering, raising approximately $432 million. The offering included 5,122,807 shares at $85.50 each, along with pre-funded warrants for 257,310 shares. The funds will support clinical trials, manufacturing operations, and general corporate purposes. The company aims to enhance its cellular immunotherapies targeting cancer and immune disorders, leveraging its iPSC product platform.

Fate Therapeutics announced a public offering of 4,421,053 shares of common stock at $85.50 each, along with pre-funded warrants for 257,310 shares at $85.499, raising approximately $400 million. The expected net proceeds are about $376 million after expenses. The funds will support clinical trials, product manufacturing, and general corporate purposes. The offering is set to close by January 8, 2021, pending customary conditions. Jefferies, BofA Securities, SVB Leerink, and Barclays are managing the offering.

Fate Therapeutics announced a public offering of $350 million in common stock, intending to utilize the net proceeds for critical activities including clinical trials, manufacturing operations expansion, and preclinical research. An additional $52.5 million option may be granted to underwriters. The offering is contingent on market conditions and will be executed under an existing shelf registration with the SEC. This strategic move aims to bolster Fate's pipeline of cellular immunotherapies for cancer and immune disorders.

Fate Therapeutics announced positive results from its Phase 1 clinical trial of FT596, an off-the-shelf NK cell therapy targeting CD19, at the Society of Hematology meeting. A heavily pre-treated patient with DLBCL achieved a partial response after administering a single dose of 30 million cells. A second treatment cycle led to a deepening response, with no serious adverse events or cytokine release syndrome reported. The duration of response was 3.8 months, comparable to autologous CAR-T therapies. The trial continues to explore higher doses and combinations.

Fate Therapeutics announced positive interim results from its Phase 1 study of FT516 in combination with rituximab for relapsed/refractory B-cell lymphoma. Of the four patients evaluable, three achieved an objective response, including two complete responses. Importantly, FT516 was well-tolerated with no severe adverse events and no cases of cytokine release syndrome. The study indicates the potential for FT516 to be administered in an outpatient setting, potentially expanding treatment options for patients. A fourth dose cohort of FT516 is planned as part of ongoing research.

Fate Therapeutics, Inc. (NASDAQ: FATE) will host a virtual event titled “The Power of hnCD16” on December 4, 2020, at 4:30 PM EDT. This event will focus on the unique therapeutic features of the hnCD16 Fc receptor, crucial in its engineered NK cell therapies. The hnCD16 is designed to enhance antibody-dependent cellular cytotoxicity, effectively targeting and killing cancer cells. The event will be accessible via the company's website, with an archived version available afterward. Fate Therapeutics specializes in developing off-the-shelf cellular immunotherapies for cancer and immune disorders.

Fate Therapeutics, Inc. (NASDAQ: FATE) has announced its participation in three upcoming investor conferences. The events include the Stifel Healthcare Virtual Conference on November 17, 2020, Jefferies Global Healthcare Virtual Conference on November 19, 2020, and Evercore ISI HealthCONx Virtual Conference on December 1, 2020. Each event will feature a live webcast available on the company's investor relations section. Fate Therapeutics focuses on developing cellular immunotherapies for cancer and immune disorders, utilizing its proprietary iPSC platform.

Fate Therapeutics reported encouraging advancements in its clinical trials for its iPSC-derived NK cell therapies. The Phase 1 study of FT596 has expanded, treating patients with B-cell lymphoma and now chronic lymphocytic leukemia. Initial patients have also been treated with FT516 in combination with avelumab for solid tumors. The company has initiated enrollment for FT538, a CRISPR-edited therapy, targeting acute myeloid leukemia and multiple myeloma. Financially, total revenue for Q3 2020 was $7.6 million, while R&D and G&A expenses were $30.7 million and $8.4 million, respectively.